Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Oct 26, 2011, 05:38 ET from Reportlinker

NEW YORK, Oct. 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0661224/Heart-Failure-HF-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the Industry analysis specialist, has released its new report, "Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information on the global Heart Failure therapeutics market, and provides analysis of a number of key areas. The report identifies the key trends shaping and driving the global Heart Failure therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Heart Failure sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The global Heart Failure (HF) therapeutics market valued at $3,269.0m in 2005, and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $4,068.5m in 2010. GlobalData analysis suggests that the global HF therapeutics market will grow at a high CAGR of 2.5% over the next eight years, to reach $5,104.1m by 2018. This growth will be primarily attributed due to the expected launch of novel, therapies relaxin and LCZ696 during the forecast period. Relaxin is expected to be launched in late 2014 and LCZ696 in 2015. An increase in the treatment seeking population due to an increase in the life expectancy and increasing awareness leading to diagnosis at an early stage will also drive the HF therapeutics market. Apart from these the HF therapeutics market will be driven by the increases in aging population which are more susceptible towards Acute Heart Failure (AHF). The current competition in the HF therapeutics market is weak, primarily dominated by generic drugs such as milirinone, dobutamine, digoxin, Coreg (carvedilol), and Altace (ramipril). Only Diavon (valsartan) and Natrecor (nesiritide) are the two branded product which are expected to lose patents in 2012 and 2014 respectively.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the Heart Failure therapeutics market. Its scope includes -

- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) Heart Failure therapeutics market revenue data for 2005–2010, and 2011–2018.

- The late stage pipeline has molecules which would affect progression of HF, known as renin inhibitor, Angiotensin receptor neprilysin (ANRI) inhibitor and vasodilators in acute case of heart failure. The other promising drugs in the HF developmental pipeline in terms of mechanism of action include a stem cell therapy, angiotensin converting enzyme inhibitor, aldosterone antagonist, natriuretic peptide receptor agonist, and glucagon-like peptide 1 agonist.

- Analysis of the current and future competition in the key countries of the Heart Failure therapeutics market. Novartis, Amgen, Cardiokline, Bayer, Nile Therapeutics, Cytokinetics, and GlaxoSmithKline are the key players, they are key market players, is covered in this section.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Heart Failure therapeutics market.

- Analysis of key recent licensing and partnership agreements in Heart Failure therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Heart Failure therapeutics market.

- Increase revenue through an understanding of the key trends, innovative products and technologies, market segments and companies likely to affect the global Heart Failure therapeutics market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Heart Failure therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 7

2 Heart Failure (HF) Therapeutics: Executive Summary 9

2.1 The HF Therapeutics Market Shows Significant Growth Until 2018 9

2.2 Current HF Therapeutics Market is Weak and is Dominated by Generics 10

2.3 Strong Pipeline Candidates Expected to Enter the Market, To Provide Better Treatment Option 11

2.4 Unmet Need Remains Unaddressed 11

3 Heart Failure (HF) Therapeutics: Introduction 13

3.1 Overview 13

3.2 Etiology 14

3.3 Pathophysiology 17

3.4 Epidemiology & Prognosis 19

3.5 Symptoms 19

3.6 Diagnosis 20

3.7 Treatment and Management Pattern 27

3.7.1 Pharmacological Therapies 27

3.7.2 Goals of treatment of the patients with HF 28

3.8 GlobalData Report Guidance 31

4 HF Therapeutics: Market Characterization 32

4.1 HF Therapeutics Market Size (2005-2010) – Global 32

4.2 HF Therapeutics Market Forecast (2010-2018) – Global 33

4.3 HF Therapeutics Market Size (2005-2010): The US 34

4.4 HF Therapeutics Market Forecast (2010-2018): The US 36

4.5 HF Therapeutics Market (2005-2010): France 37

4.6 HF Therapeutics Market Forecast (2010-2018): France 37

4.7 HF Therapeutics Market (2005-2010): Germany 38

4.8 HF Therapeutics Market Forecast (2010-2018): Germany 39

4.9 HF Therapeutics Market (2005-2010): Italy 40

4.10 HF Therapeutics Market Forecast (2010-2018): Italy 41

4.11 HF Therapeutics Market (2005-2010): Spain 42

4.12 HF Therapeutics Market Forecast (2010-2018): Spain 43

4.13 HF Therapeutics Market (2005-2010): The UK 44

4.14 HF Therapeutics Market Forecast (2010-2018): The UK 45

4.15 HF Therapeutics Market (2005-2010): Japan 46

4.16 HF Therapeutics Market Forecast (2010-2018): Japan 47

4.17 Drivers and Barriers for the HF Therapeutics Market 49

4.17.1 Drivers for the HF Therapeutics Market 49

4.17.2 Barriers for the HF Therapeutics Market 49

4.18 Opportunity and Unmet Need Analysis 50

4.19 Key Takeaway 51

5 HF Therapeutics: Competitive Assessment 52

5.1 Overview 52

5.2 Strategic Competitor Assessment 52

5.3 Product Profile for the Major Marketed Products in the HF Therapeutics Market 54

5.3.1 Natrecor (nesiritide) 54

5.3.2 Primacor (milrinone lactate) 55

5.3.3 Coreg (Carvedilol) 56

5.3.4 Altace (ramipril) 57

5.3.5 Diovan (Valsartan) 58

5.4 Key Takeaway 60

6 HF Therapeutics: Pipeline Assessment 61

6.1 Overview 61

6.2 Strategic Pipeline Assessment 61

6.3 HF Therapeutics Pipeline – Pipeline by Phases of Development 62

6.3.1 HF Therapeutics – Phase III Pipeline 62

6.3.2 HF Therapeutics – Phase II Pipeline 63

6.3.3 HF Therapeutics – Phase I Pipeline 63

6.3.4 HF Therapeutics – Preclinical Pipeline 64

6.3.5 HF Therapeutics – Discovery Pipeline 64

6.4 HF Therapeutics Market – Clinical Pipeline by Mechanism of Action 64

6.5 Technology Trends Analytical Framework 65

6.6 HF Therapeutics – Promising Drugs Under Clinical Development 67

6.7 Molecule Profile for Promising Drugs Under Clinical Development 68

6.7.1 Relaxin (RLX030) 68

6.7.2 LCZ696 69

6.7.3 Lixivaptan 69

6.7.4 Tekturna/Rasilez (aliskiren) 70

6.8 Key Takeaway 71

7 HF Therapeutics: Clinical Trials Mapping 72

7.1 Clinical Trials by Region/Country (the US, EU5, and Japan) 72

7.2 Clinical Trials by Phase 73

7.3 Clinical Trials by Trial Status 74

7.4 Clinical Trials by Overall Sponsors 75

7.5 Prominent Sponsors 76

7.6 Key Companies Participating in Therapeutics Clinical Trials 77

8 HF Therapeutics: Stategic Assessment 79

8.1 Key Events Impacting the Future Market 79

8.2 HF Therapeutics: Implications for Future Market Competition 80

9 HF Therapeutics: Future Players 82

9.1 Introduction 82

9.2 Company Profiles 83

9.2.1 Novartis AG. 83

9.2.2 Amgen Inc. 85

9.2.3 Cardiokine, Inc 87

9.2.4 Bayer AG. 88

9.2.5 Nile Therapeutics, Inc.. 90

9.2.6 Cardioxyl Pharmaceuticals, Inc 91

9.2.7 Cytokinetics, Inc 92

9.2.8 GlaxoSmithKline plc 94

9.2.9 Trevena, Inc. 95

10 HF Therapeutics: Licensing and Partnership Deals 97

11 HF Therapeutics: Appendix 98

11.1 Market Definitions 98

11.2 Acronyms 98

11.3 Research Methodologyy 99

11.3.1 Coverage 99

11.3.2 Secondary Research 100

11.3.3 Forecasting 100

11.3.4 Primary Research 103

11.3.5 Expert Panel Validation 104

11.4 Contact Us 104

11.5 Disclaimer 104

11.6 Bibliography 105

List of Tables

Table 1: Clinical Condition in HF 15

Table 2: Classification of Heart Failure by Structural Abnormality (ACC/AHA), or by Symptoms Relating to Functional Capacity (NYHA) 16

Table 3: Common Causes of HF due to Disease of Heart Muscle (Myocardial Disease) 17

Table 4: Cause and Precipitating factor in HF 18

Table 5: Assessment of Congestion 19

Table 6: Common ECG Abnormalities in HF 24

Table 7: Common Chest X-ray Abnormalities in HF 25

Table 8: Common Laboratory Test Abnormalities in HF 27

Table 9: Common Echocardiographic Abnormalities in HF 29

Table 10: HF Therapeutics Market, Global, Revenue ($m), 2005-2010 35

Table 11: HF Therapeutics Market, Global, Forecast ($m), 2010-2018 36

Table 12: HF Therapeutics Market, the US, Revenue ($m), 2005-2010 37

Table 13: HF Therapeutics Market, the US, Forecast ($m), 2010-2018 38

Table 14: HF Therapeutics Market, France, Revenue ($m), 2005-2010 39

Table 15: HF Therapeutics Market, France, Forecast ($m), 2010-2018 40

Table 16: HF Therapeutics Market, Germany, Revenue ($m), 2005-2010 41

Table 17: HF Therapeutics Market, Germany, Forecast ($m), 2010-2018 42

Table 18: HF Therapeutics Market, Italy, Revenue ($m), 2005-2010 43

Table 19: HF Therapeutics Market, Italy, Forecast ($m), 2010-2018 44

Table 20: HF Therapeutics Market, Spain, Revenue ($m), 2005-2010 45

Table 21: HF Therapeutics Market, Spain, Forecast ($m), 2010-2018 46

Table 22: HF Therapeutics Market, the UK, Revenue ($m), 2005-2010 47

Table 23: HF Therapeutics Market, the UK, Forecast ($m), 2010-2018 48

Table 24: HF Therapeutics Market, Japan, Revenue ($m), 2005-2010 49

Table 25: HF Therapeutics Market, Japan, Forecast ($m), 2010-2018 50

Table 26: HF Therapeutics – Strategic Competitor Assessment, 2011 55

Table 27: Major Marketed Product in the HF Market, 2011 62

Table 28: HF Therapeutics Market – Phase III Pipeline, 2011 64

Table 29: HF Therapeutics Market – Phase II Pipeline, 2011 65

Table 30: HF Therapeutics Market – Phase I Clinical Pipeline, 2011 65

Table 31: HF Therapeutics Market – Preclinical Clinical Pipeline, 2011 66

Table 32: HF Therapeutics Market – Discovery Clinical Pipeline, 2011 66

Table 33: Heart Failure – Most Promising Drugs Under Clinical Development, 2011 69

Table 34: HF Therapeutics Market, Clinical Trials by Region, 2011 75

Table 35: HF Therapeutics Market, Global, Clinical Trials by Phase of Development, 2011 76

Table 36: HF Therapeutics Market, Global, Clinical Trials by Trial Status, 2011 77

Table 37: HF Therapeutics Market, Global, Clinical Trials by Overall Sponsors, 2011 78

Table 38: HF Therapeutics Market, Global, Clinical Trials by Prominent Sponsors, 2011 79

Table 39: HF Therapeutics Market, Global, Clinical Trials by Lead Sponsors, 2011 80

Table 40: Pipeline Molecules 2011 87

Table 41: Pipeline Molecules 2011 89

Table 42: Pipeline Molecules 2011 89

Table 43: Pipeline Products 2011 91

Table 44: Pipeline Product 2011 93

Table 45: Pipeline Product 2011 94

Table 46: Pipeline Product 2011 96

Table 47: Product pipeline 2011 97

Table 48: Pipeline Products 2011 98

Table 49: Licensing and Partnership Deals 99

List of Figures

Figure 1: HF Therapeutics Market, Global, Revenue ($m), 2005-2018 11

Figure 2: Opportunity and Unmet Need in the HF Therapeutics Market, 2011 14

Figure 3: Pathophysiology of HF 20

Figure 4: Diagnosis Algorithm for HF 22

Figure 5: Treatment Algorithm for Acute Heart Failure with Systolic dysfunction 31

Figure 6: Treatment Algorithm for Heart Failure 32

Figure 7: HF Therapeutics Market, Global, Revenue ($m), 2005-2010 34

Figure 8: HF Therapeutics Market, Global, Forecast ($m), 2010-2018 36

Figure 9: HF Therapeutics Market, the US, Revenue ($m), 2005-2010 37

Figure 10: HF Therapeutics Market, the US, Forecast ($m), 2010-2018 38

Figure 11: HF Therapeutics Market, France, Revenue ($m), 2005-2010 39

Figure 12: HF Therapeutics Market, France, Forecast ($m), 2010-2018 40

Figure 13: HF Therapeutics Market, Germany, Revenue ($m), 2005-2010 41

Figure 14: HF Therapeutics Market, Germany, Forecast ($m), 2010-2018 42

Figure 15: HF Therapeutics Market, Italy, Revenue ($m), 2005-2010 43

Figure 16: HF Therapeutics Market, Italy, Forecast ($m), 2010-2018 44

Figure 17: HF Therapeutics Market, Spain, Revenue ($m), 2005-2010 45

Figure 18: HF Therapeutics Market, Spain, Forecast ($m), 2010-2018 46

Figure 19: HF Therapeutics Market, the UK, Revenue ($m), 2005-2010 47

Figure 20: HF Therapeutics Market, the UK, Forecast ($m), 2010-2018 48

Figure 21: HF Therapeutics Market, Japan, Revenue ($m), 2005-2010 49

Figure 22: HF Therapeutics Market, Japan, Forecast ($m), 2010-2018 50

Figure 23: Opportunity and Unmet Need in the HF Therapeutics Market, 2011 53

Figure 24: HF Therapeutics Pipeline by Phase of Clinical Development, 2011 64

Figure 25: HF Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2011 67

Figure 26: Technology Trends Analytic Framework for the HF Therapeutics Pipeline, 2011 68

Figure 27: Technology Trends Analytic Framework for the HF Therapeutics Pipeline, 2011 69

Figure 28: HF Therapeutics Market – Clinical Trials by Region, 2011 74

Figure 29: HF Therapeutics Market, Global, Clinical Trials by Phase of Development, 2011 75

Figure 30: HF Therapeutics Market, Global, Clinical Trials by Trial Status, 2011 76

Figure 31: HF Therapeutics Market, Global, Clinical Trials by Overall Sponsors, 2011 77

Figure 32: HF Therapeutics Market, Global, Clinical Trials by Prominent Sponsors, 2011 78

Figure 33: HF Therapeutics Market, Global, Clinical Trials by Top Companies, 2011 79

Figure 34: Drivers and Barriers of the HF Therapeutics Market 81

Figure 35: Implications for Future Market Competition in the HF Therapeutics Market, 2011 82

Figure 36: HF Therapeutics Market – Clinical Pipeline by Company, 2011 84

Figure 37: GlobalData Market Forecasting Model 104Novartis AG.

Amgen Inc.

Cardiokine, Inc

Bayer AG.

Nile Therapeutics, Inc..

Cardioxyl Pharmaceuticals, Inc

Cytokinetics, Inc

GlaxoSmithKline plc

Trevena, Inc.

To order this report:

Pathology Industry: Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Pathology Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com